Orexo ABOTCQX International:ORXOY
- LAST PRICE1.4000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.4000/ 7
- Ask / Lots1.6900/ 1
- Open / Previous Close0.0000 / 1.4000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Apr 26, 2024
Report from Orexo AB's annual general meeting, 26 April 2024, from 12:01PM ET on Friday Apr 26, 2024 by Dow Jones
12:01PM ET on Friday Apr 26, 2024 by Dow Jones
Apr 17, 2024
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US, from 2:17AM ET on Wednesday Apr 17, 2024 by Dow Jones
2:17AM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 2, 2024
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled, from 7:23AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:23AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Orexo AB | 52.8M | -4.1x | --- |
Scorpius Holdings Inc | 6.1M | -0.1x | --- |
Parnell Pharmaceuticals Holdings Ltd | 20.0 | 0.0x | --- |
Targeted Medical Pharma Inc | 3.0K | 0.0x | --- |
Vapor Group Inc | 27.3K | 0.0x | --- |
Scisparc Ltd | 3.4M | -1.2x | --- |
Company Information
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Contact Information
- Headquarters
- Rapsgatan 7EUPPSALA, Sweden 751 05
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- James Noble
- President, Chief Executive Officer
- Nikolaj Sorensen
- Chief Financial Officer, Executive Vice President
- Fredrik Jarrsten
- President of Orexo US Inc.
- Robert Deluca
- Senior Vice President and Head of Operations
- Cecilia Coupland
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.8M |
|---|---|
Revenue (TTM) | $58.5M |
Shares Outstanding | 34.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.34 |
Book Value | $0.16 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | 0.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -17.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
